1141 related articles for article (PubMed ID: 25155658)
1. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography.
Palmqvist S; Zetterberg H; Blennow K; Vestberg S; Andreasson U; Brooks DJ; Owenius R; Hägerström D; Wollmer P; Minthon L; Hansson O
JAMA Neurol; 2014 Oct; 71(10):1282-9. PubMed ID: 25155658
[TBL] [Abstract][Full Text] [Related]
2. Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment.
Janelidze S; Pannee J; Mikulskis A; Chiao P; Zetterberg H; Blennow K; Hansson O
JAMA Neurol; 2017 Dec; 74(12):1492-1501. PubMed ID: 29114726
[TBL] [Abstract][Full Text] [Related]
3. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
4. Amyloid-β PET-Correlation with cerebrospinal fluid biomarkers and prediction of Alzheimer´s disease diagnosis in a memory clinic.
Müller EG; Edwin TH; Stokke C; Navelsaker SS; Babovic A; Bogdanovic N; Knapskog AB; Revheim ME
PLoS One; 2019; 14(8):e0221365. PubMed ID: 31430334
[TBL] [Abstract][Full Text] [Related]
5. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
[TBL] [Abstract][Full Text] [Related]
6. [18F]-Flutemetamol Uptake in Cortex and White Matter: Comparison with Cerebrospinal Fluid Biomarkers and [18F]-Fludeoxyglucose.
Kalheim LF; Fladby T; Coello C; Bjørnerud A; Selnes P
J Alzheimers Dis; 2018; 62(4):1595-1607. PubMed ID: 29504529
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer's disease.
Adamczuk K; Schaeverbeke J; Vanderstichele HM; Lilja J; Nelissen N; Van Laere K; Dupont P; Hilven K; Poesen K; Vandenberghe R
Alzheimers Res Ther; 2015 Dec; 7(1):75. PubMed ID: 26677842
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders.
Leuzy A; Smith R; Ossenkoppele R; Santillo A; Borroni E; Klein G; Ohlsson T; Jögi J; Palmqvist S; Mattsson-Carlgren N; Strandberg O; Stomrud E; Hansson O
JAMA Neurol; 2020 Aug; 77(8):955-965. PubMed ID: 32391858
[TBL] [Abstract][Full Text] [Related]
9. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease.
Palmqvist S; Zetterberg H; Mattsson N; Johansson P; ; Minthon L; Blennow K; Olsson M; Hansson O;
Neurology; 2015 Oct; 85(14):1240-9. PubMed ID: 26354982
[TBL] [Abstract][Full Text] [Related]
10. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
11. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
[TBL] [Abstract][Full Text] [Related]
12. Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly.
Niimi Y; Janelidze S; Sato K; Tomita N; Tsukamoto T; Kato T; Yoshiyama K; Kowa H; Iwata A; Ihara R; Suzuki K; Kasuga K; Ikeuchi T; Ishii K; Ito K; Nakamura A; Senda M; Day TA; Burnham SC; Iaccarino L; Pontecorvo MJ; Hansson O; Iwatsubo T
Alzheimers Res Ther; 2024 May; 16(1):115. PubMed ID: 38778353
[TBL] [Abstract][Full Text] [Related]
13. CSF biomarkers and amyloid PET: concordance and diagnostic accuracy in a MCI cohort.
Spallazzi M; Barocco F; Michelini G; Immovilli P; Taga A; Morelli N; Ruffini L; Caffarra P
Acta Neurol Belg; 2019 Sep; 119(3):445-452. PubMed ID: 30847669
[TBL] [Abstract][Full Text] [Related]
14. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy.
Wang L; Benzinger TL; Su Y; Christensen J; Friedrichsen K; Aldea P; McConathy J; Cairns NJ; Fagan AM; Morris JC; Ances BM
JAMA Neurol; 2016 Sep; 73(9):1070-7. PubMed ID: 27454922
[TBL] [Abstract][Full Text] [Related]
16. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid.
Landau SM; Lu M; Joshi AD; Pontecorvo M; Mintun MA; Trojanowski JQ; Shaw LM; Jagust WJ;
Ann Neurol; 2013 Dec; 74(6):826-36. PubMed ID: 23536396
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
Sutphen CL; Jasielec MS; Shah AR; Macy EM; Xiong C; Vlassenko AG; Benzinger TL; Stoops EE; Vanderstichele HM; Brix B; Darby HD; Vandijck ML; Ladenson JH; Morris JC; Holtzman DM; Fagan AM
JAMA Neurol; 2015 Sep; 72(9):1029-42. PubMed ID: 26147946
[TBL] [Abstract][Full Text] [Related]
18. CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts.
Hansson O; Seibyl J; Stomrud E; Zetterberg H; Trojanowski JQ; Bittner T; Lifke V; Corradini V; Eichenlaub U; Batrla R; Buck K; Zink K; Rabe C; Blennow K; Shaw LM; ;
Alzheimers Dement; 2018 Nov; 14(11):1470-1481. PubMed ID: 29499171
[TBL] [Abstract][Full Text] [Related]
19. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
[TBL] [Abstract][Full Text] [Related]
20. Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease.
Ossenkoppele R; Smith R; Ohlsson T; Strandberg O; Mattsson N; Insel PS; Palmqvist S; Hansson O
Neurology; 2019 Feb; 92(6):e601-e612. PubMed ID: 30626656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
